Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy

Massimo Lopez; Paola Papaldo; Luigi Di Lauro; Mario Barduagni; Carlo Federico Perno; Aldo Barduagni

doi:10.1159/000225736

Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy

Massimo Lopez, Paola Papaldo, Luigi Di Lauro, Mario Barduagni, Carlo Federico Perno, Aldo Barduagni

Research output: Contribution to journal › Article › peer-review

Abstract

43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m² i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.

Original language	English
Pages (from-to)	244-247
Number of pages	4
Journal	Oncology
Volume	40
Issue number	4
DOIs	https://doi.org/10.1159/000225736
Publication status	Published - 1983

Keywords

Breast cancer
Chemotherapy
Mitomycin C

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1159/000225736

Fingerprint Dive into the research topics of 'Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy'. Together they form a unique fingerprint.

Cite this

@article{825811e224eb468eb344ac4299713e68,

title = "Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy",

abstract = "43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.",

keywords = "Breast cancer, Chemotherapy, Mitomycin C",

author = "Massimo Lopez and Paola Papaldo and {Di Lauro}, Luigi and Mario Barduagni and Perno, {Carlo Federico} and Aldo Barduagni",

year = "1983",

doi = "10.1159/000225736",

language = "English",

volume = "40",

pages = "244--247",

journal = "Oncology",

issn = "0030-2414",

publisher = "UBM Medica Healthcare Publications",

number = "4",

}

TY - JOUR

T1 - Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy

AU - Lopez, Massimo

AU - Papaldo, Paola

AU - Di Lauro, Luigi

AU - Barduagni, Mario

AU - Perno, Carlo Federico

AU - Barduagni, Aldo

PY - 1983

Y1 - 1983

N2 - 43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.

AB - 43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.

KW - Breast cancer

KW - Chemotherapy

KW - Mitomycin C

UR - http://www.scopus.com/inward/record.url?scp=0020523976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020523976&partnerID=8YFLogxK

U2 - 10.1159/000225736

DO - 10.1159/000225736

M3 - Article

C2 - 6408547

AN - SCOPUS:0020523976

VL - 40

SP - 244

EP - 247

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -